Palatin Technologies, Inc. — Form 10-Q Summary
Business context and reporting period. This filing covers the three months ended September 30, 2012, Palatin’s first quarter of fiscal 2013. Palatin is a development-stage biopharmaceutical company; its lead program is bremelanotide for female sexual dysfunction (FSD). Its other programs include PL-3994 and melanocortin compounds, including candidates being developed by AstraZeneca.
Financial highlights
| Metric | Quarter ended September 30, 2012 | Comparable 2011 quarter or prior balance-sheet date |
|---|---|---|
| Revenue | $3,806 | $27,217 |
| Operating expenses | $3.404 million | $3.394 million |
| Operating loss | $3.401 million | $3.367 million |
| Net loss | $10.453 million | $3.354 million |
| Basic and diluted net loss per share | $0.15 | $0.10 |
| Net cash used in operating activities | $4.729 million | $3.976 million |
| Cash and cash equivalents | $33.461 million | $3.827 million at June 30, 2012 |
| Current assets / current liabilities | $34.344 million / $1.630 million | $4.737 million / $3.457 million at June 30, 2012 |
| Total liabilities | $1.707 million | $3.550 million at June 30, 2012 |
Revenue was entirely from AstraZeneca-related reimbursements and declined about 86% year over year. Operating expenses were broadly unchanged: R&D was $2.343 million versus $2.284 million, and general and administrative expense was $1.061 million versus $1.109 million. Operating margin is not meaningful given minimal revenue and continuing development costs.
Net loss included a $7.069 million non-cash expense from an increase in the fair value of Series B 2012 warrants. Excluding that item, the reported loss would have been substantially lower; the filing does not present this as a separate adjusted measure. Cash flow from financing was $34.367 million, primarily reflecting $34.407 million of net proceeds from a July private placement. Investing activities used $3,930. The balance sheet reports capital lease obligations totaling approximately $36,775; no material conventional borrowing is reported.
Material changes and significant events
- On July 3, 2012, Palatin completed a private placement for $35.0 million gross proceeds and $34.407 million net proceeds. It issued 3.873 million common shares and warrants covering up to 67.476 million shares, exercisable at $0.01 per share.
- Stockholders approved increasing authorized common shares from 100 million to 200 million on September 27, 2012. This allowed the Series B warrants to be reclassified from a liability to equity; the preceding increase in their fair value produced the $7.069 million expense.
- Weighted-average shares for EPS were 71.669 million versus 34.901 million a year earlier, reflecting the warrant accounting and issuance terms. The balance sheet reported 38.948 million common shares outstanding at September 30.
- General R&D costs declined following staffing reductions and closure of laboratory operations when the facility lease expired in July 2012.
Outlook, commentary and risks
- Management said available cash was expected to fund planned operations, including analysis of the Phase 2B bremelanotide results and an FDA end-of-Phase 2 meeting request, through at least calendar 2013. The company expects significant losses in fiscal 2013 and over the next several years.
- On November 8, 2012, after quarter-end, Palatin reported positive top-line Phase 2B results: the trial met statistical significance for its primary endpoint and key secondary endpoints. The company reported the treatment was generally well tolerated; common adverse events included flushing, nausea and vomiting. Phase 3 activities were anticipated to begin in the second half of calendar 2013, subject to FDA discussions and further development decisions.
- Management stated that Phase 3 bremelanotide trials will require significant additional funding and that current resources are insufficient to complete the clinical trials required for product approval. Funding beyond 2013 is uncertain; potential sources include financing and partnerships.
- Placement agreements restrict certain equity or debt financings until September 1, 2013, subject to exceptions, and grant purchasers participation and negotiation rights in specified future financings. The warrant terms also include provisions that may require redemption in certain fundamental transactions.
- Key risks include clinical and regulatory uncertainty, future financing needs, reliance on AstraZeneca for licensed-program development, competition, and potential dilution from substantial outstanding warrants. AstraZeneca had discontinued development of AZD2820 following a serious adverse event but continued other melanocortin obesity compounds.
Important facts for investors to verify
- Full Phase 2B bremelanotide data, safety findings, and the FDA’s feedback on the planned Phase 3 program.
- Cash burn and remaining runway against management’s calendar-2013 estimate, including the financing needed for Phase 3.
- Potential dilution and share overhang from the 2012 warrants, including their $0.01 exercise price and transaction-related terms.
- Terms and practical effect of the private-placement financing restrictions and investors’ future financing rights.
- Progress and economics of the AstraZeneca collaboration, including the status of its remaining development candidates and contingent milestones.
The company reported no current legal proceedings and stated that disclosure controls were effective as of September 30, 2012.